CENRIFKI Trademark

Trademark Overview

On Wednesday, February 9, 2022, a trademark application was filed for CENRIFKI with the United States Patent and Trademark Office. The USPTO has given the CENRIFKI trademark a serial number of 97259041. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Friday, October 25, 2024. This trademark is owned by Principia Biopharma Inc.. The CENRIFKI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of multiple sclerosis
cenrifki

General Information

Serial Number97259041
Word MarkCENRIFKI
Filing DateWednesday, February 9, 2022
Status734 - FIFTH EXTENSION - GRANTED
Status DateFriday, October 25, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 19, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of multiple sclerosis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 14, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePrincipia Biopharma Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBridgewater, NJ 08807
Party NamePrincipia Biopharma Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBridgewater, NJ 08807

Trademark Events

Event DateEvent Description
Friday, March 11, 2022ASSIGNED TO EXAMINER
Saturday, February 12, 2022NEW APPLICATION ENTERED
Monday, February 14, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 11, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 30, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 19, 2022PUBLISHED FOR OPPOSITION
Tuesday, April 19, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 14, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, October 21, 2022SOU TEAS EXTENSION RECEIVED
Friday, October 21, 2022SOU EXTENSION 1 FILED
Friday, October 21, 2022SOU EXTENSION 1 GRANTED
Tuesday, October 25, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 9, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 9, 2023SOU EXTENSION 2 FILED
Tuesday, May 9, 2023SOU EXTENSION 2 GRANTED
Thursday, May 11, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 6, 2023SOU TEAS EXTENSION RECEIVED
Monday, November 6, 2023SOU EXTENSION 3 FILED
Monday, November 6, 2023SOU EXTENSION 3 GRANTED
Wednesday, November 8, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 24, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, April 24, 2024SOU EXTENSION 4 FILED
Wednesday, April 24, 2024SOU EXTENSION 4 GRANTED
Friday, October 25, 2024SOU TEAS EXTENSION RECEIVED
Friday, October 25, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 25, 2024SOU EXTENSION 5 GRANTED
Friday, October 25, 2024SOU EXTENSION 5 FILED
Thursday, April 25, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

cenrifki sclerosis multiple treatment preparations pharmaceutical